

## Cyclocondensation of 2-alkoxy-2-isocyanato-3,3,3-trifluoropropionates with primary amines

V. B. Sokolov,\* T. V. Goreva, T. A. Epishina, and A. Yu. Aksinenko

Institute of Physiologically Active Substances, Russian Academy of Sciences,  
1 Severnyi proezd, 142432 Chernogolovka, Moscow Region, Russian Federation.  
Fax: +7 (496) 524 9508. E-mail: alaks@ipac.ac.ru

Cyclocondensation of ethyl 2-alkoxy-2-isocyanato-3,3,3-trifluoropropianates (novel 1,4-bielectrophiles) with primary amines resulted in 5-trifluoromethylimidazolidine-2,4-diones.

**Key words:** isocyanates, amines, imidazolidine-2,4-diones, organofluorine compounds, 1,4-bielectrophiles, cyclocondensation, heterocyclization.


Earlier,<sup>1</sup> we reported on the synthesis of novel poly-functional  $\alpha$ -substituted isocyanates, esters of 2-alkoxy-2-isocyanato-3,3,3-trifluoropropionic acids. They are promising intermediates for the synthesis of various acyclic 3,3,3-trifluoroalanine derivatives substituted at the position 2. The latter, taking into account the high bacteriostatic activity of 3,3,3-fluoroalanine, are potent biologically active substances.<sup>2,3</sup> These compounds can be regarded as derivatives of trifluoropyruvates; some of them, e.g., *N*-substituted imines of trifluoropyruvates, are successfully used for the synthesis of fluorinated heterocyclic compounds,<sup>4–8</sup> also as 1,3-bielectrophiles in the cyclocondensation reactions.<sup>9–13</sup> In the present work, we studied chemical behavior of these novel 1,4-bielectrophiles, ethyl 2-alkoxy-2-isocyanato-3,3,3-trifluoropropionates **1a,b**, in the cyclocondensation with primary amines **2a–k** (Scheme 1).

Reaction of isocyanates **1a,b** with amines **2a–k** acting in these transformations as 1,1-binucleophiles proceeded as cyclocondensation involving (1) addition of amine to the C=N bond to give the corresponding urea **3** and (2) subsequent heterocyclization with removal of EtOH to yield imidazolidine-2,4-diones **4a–l**. Reactions were performed by mixing equimolar amounts of isocyanate **1** and amine **2** in DMF at 20 °C with further heating of the reaction mixture at 90–100 °C for 2 h in the presence of catalytic amounts of Et<sub>3</sub>N.

In the case of isocyanate **1a** and 3-chloroaniline **2b**, we succeeded to isolate and characterize the individual intermediate adducts, urea **3a**. The latter was converted into imidazolidine-2,4-dione **4a** by heating in DMF at 90–100 °C for 2 h in the presence of catalytic amounts of Et<sub>3</sub>N (Scheme 2).

Imidazolidine-2,4-diones **4a–l** synthesized in 65–79% yields are crystalline compounds. Composition and structure of **4a–l** were established by elemental analysis and

Scheme 1



**1:** Alk = Et (**a**), Pr (**b**)

**2:** R = Ph (**a**), 3-ClC<sub>6</sub>H<sub>4</sub> (**b**), 4-MeOC<sub>6</sub>H<sub>4</sub> (**c**), 4-Me<sub>2</sub>CHC<sub>6</sub>H<sub>4</sub> (**d**), 3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub> (**e**), 4-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub> (**f**), 3-Cl-4-FC<sub>6</sub>H<sub>3</sub> (**g**), 5-F-2-MeC<sub>6</sub>H<sub>3</sub> (**h**), 5-Cl-2-MeOC<sub>6</sub>H<sub>3</sub> (**i**), CH<sub>2</sub>CH<sub>2</sub>Ph (**j**), 2-PyCH<sub>2</sub> (**k**)

**4:** Alk = Et, R = 3-ClC<sub>6</sub>H<sub>4</sub> (**a**), 4-MeOC<sub>6</sub>H<sub>4</sub> (**b**), 3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub> (**c**),


3-Cl-4-FC<sub>6</sub>H<sub>3</sub> (**d**), 2-Me-5-FC<sub>6</sub>H<sub>3</sub> (**e**)

Alk = Pr, R = Ph (**f**), CH<sub>2</sub>CH<sub>2</sub>Ph (**g**), 2-PyCH<sub>2</sub> (**h**), 4-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub> (**i**), 4-Me<sub>2</sub>CHC<sub>6</sub>H<sub>4</sub> (**j**), 3-ClC<sub>6</sub>H<sub>4</sub> (**k**), 5-Cl-2-MeOC<sub>6</sub>H<sub>3</sub> (**l**)

<sup>1</sup>H and <sup>19</sup>F NMR spectroscopy. <sup>19</sup>F and NMR spectra exhibited singlets in the range of δ –(2–3) characteristic of the trifluoromethyl group; <sup>1</sup>H NMR spectra contained singlets in the range of δ 10–11 attributed to the protons of the NH group.

In summary, in the present work we introduced novel 1,4-bielectrophiles promising for cyclocondensation re-

Scheme 2



actions, esters of 2-alkoxy-2-isocyanato-3,3,3-trifluoropropionic acids. These compounds could be used for the synthesis of various fluorinated hydantoins. It is of note

that hydantoins are widely used in medical (anticonvulsants,<sup>14</sup> anticancer<sup>15</sup> agents) and agrochemical (herbicides<sup>16</sup>) practice.

## Experimental

<sup>1</sup>H and <sup>19</sup>F NMR spectra were recorded on a Bruker DPX 200 spectrometer (200.13 and 188.29 MHz, respectively) relative to Me<sub>4</sub>Si (internal standard) and CF<sub>3</sub>COOH (external standard), respectively. Melting points were determined in the glass capillary and uncorrected. The starting isocyanates **1a,b** were synthesized according to the known procedure,<sup>1</sup> amines **2a–k** (Aldrich) were used as purchased.

**Ethyl 2-[3-(3-chlorophenyl)ureido]-2-ethoxy-3,3,3-trifluoropropionate (3a).** To a solution of isocyanate **1a** (0.01 mol) in benzene (20 mL), aniline **2b** (0.01 mol) was added. After completion of the exothermic reaction, the mixture was stirred for 2 h, the solvent was removed *in vacuo*, the residue was recrystallized from hexane. Yield, melting points, elemental analysis data, and spectral data for compound **3a** are given in Tables 1 and 2.

**3-(3-Chlorophenyl)-5-ethoxy-5-trifluoromethylimidazolidine-2,4-dione (4a). A.** To a solution of urea **3a** (0.01 mol) in DMF (10 mL), Et<sub>3</sub>N (0.1 g) was added. The reaction mixture was heated at 80 °C for 1 h, then water (50 mL) was added, the precipitate formed was recrystallized from hexane.

Tables 1. Yields, melting points, and elemental analysis data for compounds **3a** and **4a–l**

Com- ound	Yield (%)	M.p./°C	Molecular formula	Found Calculated (%)		
				C	H	N
<b>3a</b>	88	142–143	C <sub>14</sub> H <sub>16</sub> ClF <sub>3</sub> N <sub>2</sub> O <sub>4</sub>	46.74 45.60	4.51 4.37	7.82 7.60
<b>4a</b>	81(A), 73 (B)	107–108	C <sub>12</sub> H <sub>10</sub> ClF <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	44.67 44.78	3.12 3.34	8.68 8.51
<b>4b</b>	65	161–162	C <sub>13</sub> H <sub>13</sub> F <sub>3</sub> N <sub>2</sub> O <sub>4</sub>	46.06 46.21	4.12 4.35	8.80 8.59
<b>4c</b>	72	75–76	C <sub>13</sub> H <sub>10</sub> F <sub>6</sub> N <sub>2</sub> O <sub>3</sub>	43.83 43.64	2.83 2.98	7.86 7.58
<b>4d</b>	74	126–127	C <sub>12</sub> H <sub>9</sub> ClF <sub>4</sub> N <sub>2</sub> O <sub>3</sub>	42.31 42.12	2.66 2.45	8.22 8.44
<b>4e</b>	69	127–128	C <sub>13</sub> H <sub>12</sub> F <sub>4</sub> N <sub>2</sub> O <sub>3</sub>	48.76 78.57	3.78 3.95	8.75 8.56
<b>4f</b>	68	84–85	C <sub>13</sub> H <sub>13</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	51.66 51.47	4.34 4.15	9.27 9.05
<b>4g</b>	79	97–98	C <sub>15</sub> H <sub>17</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	54.54 54.36	5.19 5.36	8.48 8.29
<b>4h</b>	75	107–108	C <sub>13</sub> H <sub>14</sub> F <sub>3</sub> N <sub>3</sub> O <sub>3</sub>	49.22 49.03	4.45 4.27	13.24 13.45
<b>4i</b>	71	91–92	C <sub>14</sub> H <sub>12</sub> F <sub>6</sub> N <sub>2</sub> O <sub>3</sub>	45.42 45.26	3.27 3.12	7.57 7.35
<b>4j</b>	66	110–111	C <sub>16</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	55.81 55.63	5.56 5.38	8.14 8.32
<b>4k</b>	79	74–75	C <sub>13</sub> H <sub>12</sub> ClF <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	46.38 46.17	3.59 3.75	8.32 8.14
<b>4l</b>	73	116–118	C <sub>14</sub> H <sub>14</sub> ClF <sub>3</sub> N <sub>2</sub> O <sub>4</sub>	45.85 45.59	3.85 3.62	7.64 7.46

**Table 2.**  $^1\text{H}$  and  $^{19}\text{F}$  NMR spectra (DMSO-d<sub>6</sub>) of compounds **3a** and **4a–l**

Compound	$^1\text{H}$ NMR, $\delta$ (J/Hz)	$^{19}\text{F}$ NMR, $\delta$
<b>3a</b>	1.26 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.32 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> O, $J$ = 7.5); 3.72–3.94 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> O); 4.31 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> O); 6.64 (s, 1 H, CH <sub>Ar</sub> ); 7.12 (m, 1 H, CH <sub>Ar</sub> ); 7.28 (m, 2 H, CH <sub>Ar</sub> ); 7.56 (s, 1 H, NH); 7.68 (s, 1 H, NH)	-0.24 (s, CF <sub>3</sub> )
<b>4a</b>	1.31 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> O, $J$ = 7.4); 3.72–3.94 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> O); 6.64 (s, 1 H, CH <sub>Ar</sub> ); 7.12 (m, 1 H, CH <sub>Ar</sub> ); 7.28 (m, 2 H, CH <sub>Ar</sub> ); 9.56 (s, 1 H, NH)	-2.12 (s, CF <sub>3</sub> )
<b>4b</b>	1.42 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> O, $J$ = 7.6); 3.69 (s, 3 H, MeO); 3.92–4.21 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> O); 6.81, 7.32 (both d, 2 H, CH <sub>Ar</sub> , $J$ = 8.6); 10.05 (s, 1 H, NH)	-2.16 (s, CF <sub>3</sub> )
<b>4c</b>	1.35 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> O, $J$ = 7.4); 3.78–4.01 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> O); 7.15–7.26 (m, 2 H, CH <sub>Ar</sub> ); 7.36 (m, 2 H, CH <sub>Ar</sub> ); 9.88 (s, 1 H, NH)	-2.8 (s, CF <sub>3</sub> ); 15.71 (s, CF <sub>3</sub> )
<b>4d</b>	1.22 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> O, $J$ = 7.5); 3.98 (m, 1 H, CH <sub>3</sub> CH <sub>2</sub> O); 4.28 (m, 1 H, CH <sub>3</sub> CH <sub>2</sub> O); 7.23 (m, 2 H, CH <sub>Ar</sub> ); 7.41 (m, 1 H, CH <sub>Ar</sub> ); 10.12 (s, 1 H, NH)	-37.02 (m, 1 F, CF <sub>Ar</sub> ); -2.11 (s, 3 F, CF <sub>3</sub> )
<b>4e</b>	1.22 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> O, $J$ = 7.5); 2.12 (s, 3 H, Me); 3.84 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> O); 7.12 (m, 1 H, CH <sub>Ar</sub> ); 7.28 (m, 2 H, CH <sub>Ar</sub> ); 9.98 (s, 1 H, NH)	-37.93 (m, 1 F, CF <sub>Ar</sub> ); -2.24 (s, 3 F, CF <sub>3</sub> )
<b>4f</b>	1.10 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.82 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 3.99 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 6.98–7.29 (m, 5 H, CH <sub>Ar</sub> ); 9.81 (s, 1 H, NH)	-2.35 (s, CF <sub>3</sub> )
<b>4g</b>	1.10 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.82 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 2.80 (t, 2 H, PhCH <sub>2</sub> CH <sub>2</sub> , $J$ = 8.3); 3.82 (t, 2 H, PhCH <sub>2</sub> CH <sub>2</sub> , $J$ = 8.3); 3.99 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 6.98–7.29 (m, 5 H, CH <sub>Ar</sub> ); 9.81 (s, 1 H, NH)	-2.43 (s, CF <sub>3</sub> )
<b>4h</b>	0.99 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.88 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 4.02 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 5.06 (s, 2 H, CH <sub>2</sub> ); 7.32 (t, 1 H, CH <sub>Ar</sub> , $J$ = 7.3); 7.65 (d, 1 H, CH <sub>Ar</sub> , $J$ = 7.3); 8.35–8.62 (m, 2 H, CH <sub>Ar</sub> ); 10.23 (s, 1 H, NH)	-2.14 (s, CF <sub>3</sub> )
<b>4i</b>	1.12 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.87 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 3.91 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 7.12, 7.26 (both m, 2 H, CH <sub>Ar</sub> ); 10.08 (s, 1 H, NH)	-2.71 (s, CF <sub>3</sub> ); -15.96 (s, CF <sub>3</sub> )
<b>4j</b>	0.96 (d, 6 H, Me, $J$ = 7.1); 1.08 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.92 (m, 1 H, Me <sub>2</sub> CH); 1.79 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 3.89 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 6.81, 7.13 (both d, 2 H, CH <sub>Ar</sub> , $J$ = 8.1); 10.15 (s, 1 H, NH)	-2.20 (s, CF <sub>3</sub> )
<b>4k</b>	1.08 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.79 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 3.89 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 6.88 (s, 1 H, CH <sub>Ar</sub> ); 7.19 (m, 1 H, CH <sub>Ar</sub> ); 7.36 (m, 2 H, CH <sub>Ar</sub> ); 9.86 (s, 1 H, NH)	-2.18 (s, CF <sub>3</sub> )
<b>4l</b>	1.02 (t, 3 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O, $J$ = 7.5); 1.79 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 3.71 (s, 3 H, MeO); 3.89 (m, 2 H, CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O); 7.02 (s, 1 H, CH <sub>Ar</sub> ); 7.28 (d, 1 H, CH <sub>Ar</sub> , $J$ = 7.9); 7.46 (d, 1 H, CH <sub>Ar</sub> , $J$ = 7.9); 10.16 (s, 1 H, NH)	-2.21 (s, CF <sub>3</sub> )

**B.** To a stirred solution of aniline **2a** (0.01 mol) in DMF (10 mL), isocyanate **1a** (0.01 mol) was added at 20 °C. The reaction mixture was stirred for 1 h, then Et<sub>3</sub>N (0.1 g) was added and the mixture was heated at 80 °C for 1 h. Water (50 mL) was added, the precipitate formed was recrystallized from hexane. Yield, melting point, elemental analysis data, and spectral data for compound **4a** are given in Tables 1 and 2.

**5-Ethoxy-3-(4-methoxyphenyl)-5-trifluoromethylimidazolidine-2,4-dione (4b), 5-ethoxy-5-trifluoromethyl-3-(3-trifluoromethylphenyl)imidazolidine-2,4-dione (4c), 3-(3-chloro-4-fluorophenyl)-5-ethoxy-5-trifluoromethylimidazolidine-2,4-dione (4d), 5-ethoxy-3-(5-fluoro-2-methylphenyl)-5-trifluoromethylimidazo-**

**lidine-2,4-dione (4e), 3-phenyl-5-propoxy-5-trifluoromethylimidazolidine-2,4-dione (4f), 3-(2-phenylethyl)-5-propoxy-5-trifluoromethylimidazolidine-2,4-dione (4g), 5-propoxy-3-(pyridin-2-ylmethyl)-5-trifluoromethylimidazolidine-2,4-dione (4h), 5-propoxy-5-trifluoromethyl-3-(4-trifluoromethylphenyl)imidazolidine-2,4-dione (4i), 3-(4-isopropylphenyl)-5-propoxy-5-trifluoromethylimidazolidine-2,4-dione (4j), 3-(3-chlorophenyl)-5-propoxy-5-trifluoromethylimidazolidine-2,4-dione (4k), and 3-(5-chloro-2-methoxyphenyl)-5-propoxy-5-trifluoromethylimidazolidine-2,4-dione (4l)** were synthesized similarly to the method **B**. Yields, melting points, elemental analysis data, and spectral data for compounds **4b–l** are given in Tables 1 and 2.

This work was financially supported by the Department of Chemistry and Materials Science of the Russian Academy of Sciences (program "Medicinal and Bio-medicinal Chemistry").

## References

1. V. B. Sokolov, T. V. Goreva, T. A. Epishina, A. Yu. Aksinenko, *Izv. Akad. Nauk, Ser. Khim.*, 2009, 1488 [*Russ. Chem. Bull., Int. Ed.*, 2009, **58**, 1533].
2. C. W. Fearon, J. A. Rodkey, R. H. Abeles, *Biochemistry*, 1982, **21**, 3790.
3. R. Smits, C. D. Cadicamo, K. Burger, B. Koks, *Chem. Soc. Rev.*, 2008, **37**, 1727.
4. A. V. Fokin, A. F. Kolomiets, N. V. Vasil'ev, *Usp. Khim.*, 1984, **53**, 398 [*Russ. Chem. Rev. (Engl. Transl.)*, 1984, **53**].
5. S. N. Osipov, A. F. Kolomiets, A. V. Fokin, *Usp. Khim.*, 1992, **61**, 1457 [*Russ. Chem. Rev. (Engl. Transl.)*, 1992, **61**].
6. A. Yu. Aksinenko, V. B. Sokolov, O. V. Korenchenko, A. N. Chekhlov, E. A. Fokin, I. V. Martynov, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1989, 2815 [*Bull. Acad. Sci. USSR, Div. Chem. Sci. (Engl. Transl.)*, 1989, **38**, 2580].
7. V. B. Sokolov, A. Yu. Aksinenko, *Izv. Akad. Nauk, Ser. Khim.*, 1998, 748 [*Russ. Chem. Bull. (Engl. Transl.)*, 1998, **47**, 727].
8. S. N. Osipov, A. F. Kolomiets, A. V. Fokin, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1988, 132 [*Bull. Acad. Sci. USSR, Div. Chem. Sci. (Engl. Transl.)*, 1989, **37**, 122].
9. V. B. Sokolov, A. Yu. Aksinenko, T. A. Epishina, T. V. Goreva, A. N. Pushin, I. V. Martynov, *Izv. Akad. Nauk, Ser. Khim.*, 2005, 1619 [*Russ. Chem. Bull., Int. Ed.*, 2005, **54**, 1667].
10. V. B. Sokolov, A. Yu. Aksinenko, *Izv. Akad. Nauk, Ser. Khim.*, 2005, 1470 [*Russ. Chem. Bull., Int. Ed.*, 2005, **54**, 1514].
11. V. B. Sokolov, A. Yu. Aksinenko, *Izv. Akad. Nauk, Ser. Khim.*, 2006, 706 [*Russ. Chem. Bull., Int. Ed.*, 2006, **55**, 731].
12. V. B. Sokolov, A. Yu. Aksinenko, *Zh. Obshch. Khim.*, 2010, **80**, 117 [*Russ. J. Gen. Chem. (Engl. Transl.)*, 2010, **80**].
13. A. Yu. Aksinenko, T. V. Goreva, T. A. Epishina, A. N. Pushin, V. B. Sokolov, *Izv. Akad. Nauk, Ser. Khim.*, 2006, 1014 [*Russ. Chem. Bull., Int. Ed.*, 2006, **55**, 1052].
14. W. J. Brouillette, V. P. Jestkov, M. L. Brown, M. S. Akhtar, *J. Med. Chem.*, 1994, **37**, 3289.
15. R. F. Struck, M. C. Kirk, L. S. Rice, W. J. Suling, *J. Med. Chem.*, 1986, **29**, 1319.
16. H. Ohta, T. Jikihara, K. Wakabayashi, T. Fujita, *Pestic. Biochem. Physiol.*, 1980, **14**, 153.

Received July 7, 2011;  
in revised form January 20, 2012